

WHAT IS CLAIMED IS:

1. A method of treatment for patients severely infected with anthrax using passive hyperimmune antibody therapy, comprising:
 - deriving a supply of plasma from previously vaccinated individuals;
 - processing the plasma derived therefrom to provide a preparation of gammaglobulins having a high titer of neutralizing antibodies to anthrax, the processed plasma being sterilized and free of any impurities; and
 - administering the processed plasma to the infected patient.
2. The method of claim 1, wherein anthrax is an acute infectious disease of the spore-forming bacterium *Bacillus anthracis*.
3. The method of claim 2, wherein the plasma is derived from individuals previously vaccinated with anthrax vaccine.
4. The method of claim 2, wherein the plasma is derived from individuals previously vaccinated with an antigen of *Bacillus anthracis*.
5. The method of claim 2, wherein the plasma is derived from individuals previously vaccinated with at least one of any component and any toxin produced by *Bacillus anthracis*.
6. The method of claim 5, wherein the toxin antigens are selected from the group

10027478, 122101

consisting of protective antigen, lethal factor, and oedema factor.

7. The method of claim 1, wherein the plasma derived from vaccinated individuals is collected by at least one of the methods of manual and automated plasmapheresis.

8. The method of claim 1, wherein the processed plasma is derived from at least fifty individuals and is pooled into large batches prior to administering the processed plasma to the infected patient.

9. The method of claim 1, wherein processed plasma is fractionated to produce gammaglobulin.

10. The method of claim 9, wherein the processed plasma is fractionated by Cohn fractionation.

11. The method of claim 9, wherein the processed plasma is fractionated by chromatography fractionation.

12. The method of claim 9, wherein the fractionated plasma is administered therapeutically by IV infusion in a safe and effective dose.

13. The method of claim 9, wherein the fractionated plasma is administered therapeutically by intramuscular injection in a safe and effective dose.

10027478.1E2101

14. The method of claim 1, wherein the processed plasma is administered therapeutically by plasma infusion in a safe and effective dose.

10027478-122101